Bariatric Surgery May Cut Costs and Weight More Than GLP-1 Drugs
Despite growing prescription numbers and spending on glucagon-like peptide 1 (GLP-1) receptor agonists for obesity treatment, metabolic bariatric surgery may result in greater weight loss and lower costs, according to a recent study in JAMA Surgery. This comes as obesity experts have noticed decreased demand for the weight-loss surgery, which is often considered the “last […]
STAT+: Pharmalittle: We’re reading about FDA disarray, microdosing GLP-1 weight loss drugs, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have cool breezes and clear blue skies greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for […]
STAT+: News you need to know about AI medical coding and GLP-1 microdosing
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Telehealth companies Noom, Found, and Hims & Hers have all recently launched programs to prescribe “microdosed” GLP-1s. The companies say that in small doses […]
What you need to know about AI medical coding and GLP-1 microdosing – statnews.com
What you need to know about AI medical coding and GLP-1 microdosing statnews.com
STAT+: Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates
Metsera said Tuesday that Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer coming in higher, valuing the company for up to $10 billion. Under Novo’s new proposal, it would pay $62.20 per share in exchange for half of Metsera’s shares upon signing the deal (up from its […]
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA investigational proprietary biologic combination) in a well-characterized in vivo lipopolysaccharide […]
Is Eli Lilly a Millionaire Maker?
Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor Merck (NYSE: MRK) and a nearly 30% decline for Pfizer (NYSE: PFE). There’s one very big story supporting Eli Lilly’s stock price […]
Novo Roundtrips GLP-1 Craze Ahead Of Earnings As Goldman Maps Out Next Wave Of Obesity-Drug Catalysts
Novo Roundtrips GLP-1 Craze Ahead Of Earnings As Goldman Maps Out Next Wave Of Obesity-Drug Catalysts The rollercoaster ride of the GLP-1 craze and bust cycle for Novo Nordisk A/S shares has been wild to observe over the last several years. The stock has since returned to roughly pre-GLP-1-boom levels, down 50% year-to-date amid intensifying obesity-drug competition […]
Is Eli Lilly a Millionaire Maker?
Key Points Eli Lilly’s GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company’s weight loss drug success. Weight loss drugs are set to become a disproportionate share of Lilly’s business. 10 stocks we like better than Eli Lilly › Pharmaceutical maker Eli […]
Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]